Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

7.5%

Beneficial ownership of this reported class.

Shares

8,943,712 shares

Shares beneficially owned as disclosed.

Event date

18 Aug 2025

Date tied to the ownership event or amendment.

Accepted by SEC

20 Aug 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
ARQT
Shares outstanding
119,249,493 shares
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
SCHEDULE 13D/A
Accepted by SEC
20 Aug 2025, 17:19:44 UTC
Event date
18 Aug 2025
Source filing
View source filing
Filing notes and source

Key filing fact

Frazier Life Sciences VIII, L.P. disclosed 7.5% ownership in ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, par value $0.0001 per share (ARQT) on 18 Aug 2025.

Key facts

  • Frazier Life Sciences VIII, L.P. filed SCHEDULE 13D/A for ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, par value $0.0001 per share (ARQT).
  • Disclosed ownership: 7.5%.
  • Date of event: 18 Aug 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 20 Aug 2025, 17:19.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (20)

Names, ownership percentages, voting power, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power CIK
Frazier Life Sciences VIII, L.P. 7.3% 8,785,284 0 8,785,284 0001655827
FHM LIFE SCIENCES VIII, L.P. 7.4% 8,785,284 0 8,785,284 0001698755
FHM LIFE SCIENCES VIII, L.L.C. 7.4% 8,785,291 0 8,785,291 0001698823
Frazier Life Sciences X, L.P. 0% 27,448 0 27,448 0001790879
FHMLS X, L.P. 0% 27,448 0 27,448 0001790880
FHMLS X, L.L.C. 0% 27,448 0 27,448 0001790811
Frazier Life Sciences Public Fund, L.P. 0.6% 664,973 0 664,973 0001863769
FHMLSP, L.P. 0.6% 664,973 0 664,973 0001879466
FHMLSP, L.L.C. 0.6% 664,973 0 664,973 0001879465
Frazier Life Sciences Public Overage Fund, L.P. 0.2% 196,170 0 196,170 0001913804
FHMLSP Overage, L.P. 0.2% 196,170 0 196,170 0001963247
FHMLSP Overage, L.L.C. 0.2% 196,170 0 196,170 0001963248
Frazier Life Sciences XI, L.P. 0.1% 73,087 0 73,087 0001911592
FHMLS XI, L.P. 0.1% 73,087 0 73,087 0001911580
FHMLS XI, L.L.C. 0.1% 73,087 0 73,087 0001911623
Frazier Life Sciences XII, L.P. 0.1% 127,549 0 127,549 0002052255
FHMLS XII, L.P. 0.1% 127,549 0 127,549 0002052246
FHMLS XII, L.L.C. 0.1% 127,549 0 127,549 0002052177
James N. Topper 7.4% 8,843,386 30,647 8,812,739 0001341382
Patrick J. Heron 7.5% 8,943,712 130,973 8,812,739 0001365617
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .